Trials / Unknown
UnknownNCT05364047
Clinical Trial of SARS-CoV-2 mRNA Vaccine in China
Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) in Chinese People Aged 18 Years and Over
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 144 (actual)
- Sponsor
- AIM Vaccine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is a phase I clinical trial. The investigators intent to evaluate the safety, tolerability and preliminary immunogenicity of SARS-CoV-2 mRNA vaccine (LVRNA009) in Chinese people aged 18 years and over.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Low-dose of LVRNA009 | 25μg/person |
| BIOLOGICAL | Middle-dose of LVRNA009 | 50μg/person |
| BIOLOGICAL | High-dose of LVRNA009 | 100μg/person |
| OTHER | Placebo | 0.5ml/person |
Timeline
- Start date
- 2021-07-31
- Primary completion
- 2022-10-14
- Completion
- 2023-10-01
- First posted
- 2022-05-06
- Last updated
- 2022-12-05
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05364047. Inclusion in this directory is not an endorsement.